Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg‐proline‐interferon alpha‐2b-Reference-Cited by-同舟云学术

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg‐proline‐interferon alpha‐2b

Published:2015-03-02 Issue:4 Volume:90 Page:288-294
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Them Nicole C.C.¹,Bagienski Klaudia¹,Berg Tiina¹,Gisslinger Bettina²,Schalling Martin²,Chen Doris¹,Buxhofer‐Ausch Veronika³⁴,Thaler Josef⁵,Schloegl Ernst⁶,Gastl Guenther A.⁷,Wolf Dominik⁷⁸,Strecker Karin³,Egle Alexander⁹,Melchardt Thomas⁹,Burgstaller Sonja⁵,Willenbacher Ella⁷,Zagrijtschuk Oleh¹⁰,Klade Christoph¹⁰,Greil Richard⁹,Gisslinger Heinz²,Kralovics Robert¹²

Affiliation:

1. CeMM Research Center for Molecular Medicine of the Austrian Academy of SciencesVienna Austria

2. Department of Internal Medicine IDivision of Hematology and Blood CoagulationMedical University of ViennaVienna Austria

3. 2nd Medical DepartmentSozialmedizinisches Zentrum Ost—DonauspitalVienna Austria

4. Interne 1 Hemato‐OncologyKrankenhaus Der Elisabethinen LinzLinz Austria

5. Department of Internal Medicine IVWels‐Grieskirchen HospitalWels Austria

6. Third Medical DepartmentHanusch HospitalVienna Austria

7. Department of Internal Medicine V Haematology & OncologyInnsbruck Medical UniversityInnsbruck Austria

8. Medical Clinic IIIOncologyHematology and RheumatologyUniversity Clinic of Bonn (UKB)Bonn Germany

9. Laboratory for Immunological and Molecular Cancer ResearchDepartment of Internal Medicine III with HematologyMedical OncologyHemostaseologyInfectious DiseasesRheumatologyOncologic Center, Paracelsus Medical UniversitySalzburg Austria

10. AOP Orphan Pharmaceuticals AGVienna Austria

Funder

Austrian Science Fund

AOP Orphan Pharmaceuticals AG

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.23928

Reference37 articles.

1. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes